NMR STRUCTURAL STUDIES OF DNA BINDING DOMAIN OF CBF?
NMR STRUCTURAL STUDIES OF DNA BINDING DOMAIN OF CBF?
批准号:
6298163
负责人:
JOHN Hackett BUSHWELLER
金额:
$0.75万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-03-01 至 2000-02-29
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Core binding factor (CBF) was originally identified as a
DNA-binding protein that specifically binds to the asymmetric sequence
PyGPyGGT, corresponding to the highly conserved "core" site in
mammalian type C retrovirus enhancers. CBF binding sites have
subsequently been identified in a number of T-cell specific genes,
providing evidence for the role of CBF as a T-cell transcription
factor. Additional support for CBF's role as a T-cell transcription
factor has recently come from knockout mice in which hematopoiesis was
found to be blocked at an early stage. Isolation and subsequent
cloning of CBF showed the protein to be a heteromer consisting of an ?
and ? subunit. The ? subunit contacts the DNA directly, whereas the ?
subunit does not, as indicated by the lack of any changes in the
number of phosphate contacts made by ? in the presence of ?. Binding
of the ? subunit to the ? subunit increases the affinity of the ?
subunit for the DNA sixfold without altering the sequence specificity.
The ? subunit contains a 128 amino acid region displaying a high
homology to the Drosophila segmentation protein called Runt. This 128
amino acid domain is referred to as the Runt domain. Glutathione
S-Transferase (GST) fusion proteins with the Runt domain alone have
shown this domain is responsible for both the DNA-binding and
?-binding capabilities of the ? subunit. Two of the four genes
encoding CBF subunits are proto-oncogenes commonly activated in human
leukemias. The inversion and translocations identified in these genes
are associated with 30% of de novo acute myeloid leukemias in humans.
The importance of CBF in leukemia as well as in its normal role as a
transcription factor make elucidation of its function at the molecular
level extremely interesting and potentially therapeutically useful.
In addition, the lack of any resemblance of the Runt domain or CBF?
to any known structural motifs makes them important targets for
structure determination. The ultimate objective of our work is the
structural characterization of the relevant domains of both subunits
of CBF using NMR. The aim of this proposal is the complete NMR
heteronuclear assignment and structure determination of a Runt
domain-DNA complex. The Runt domain construct we have prepared is a
176 amino acid fragment of the ? subunit. This is complexed to an 18
bp DNA duplex to obtain a well-behaved protein-DNA complex.
Preliminary 15N-1H HSQC spectra of this complex with 15N-labeled Runt
domain showed very low dispersion in the HSQC spectrum which required
a 750 MHz instrument to be resolved. Additionally, we have not, to
this point, reached concentrations higher than 0.7 mM for this
complex, thus also requiring a high field magnet to obtain adequate
signal-to-noise. Due to the >30 kDa size of this complex, we have
chosen to label the protein with 50% 2H as well as 13C/15N for
assignments via triple resonance experiments. This inclusion of 2H
should, as has been shown for the trp repressor-DNA complex for
example, increase the relevant T2's to values that permit the
recording of triple resonance experiments for the assignment process
as well as NOESY spectra for structure determination.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
AF9(MLLT3) Function in Leukemia and Normal Hematopoiesis
-
批准号:10378336
-
项目类别:
-
资助金额:$6.78万
-
财政年份:2019
-
负责人:JOHN Hackett BUSHWELLER
-
依托单位:
AF9(MLLT3) Function in Leukemia and Normal Hematopoiesis
-
批准号:10434785
-
项目类别:
-
资助金额:$58.98万
-
财政年份:2019
-
负责人:JOHN Hackett BUSHWELLER
-
依托单位:
Small Molecule Inhibitors of a Reader of DNA Methylation
-
批准号:9808362
-
项目类别:
-
资助金额:$20.19万
-
财政年份:2019
-
负责人:JOHN Hackett BUSHWELLER
-
依托单位:
AF9(MLLT3) Function in Leukemia and Normal Hematopoiesis
-
批准号:10667450
-
项目类别:
-
资助金额:$58.98万
-
财政年份:2019
-
负责人:JOHN Hackett BUSHWELLER
-
依托单位:
AF9(MLLT3) Function in Leukemia and Normal Hematopoiesis
-
批准号:10524126
-
项目类别:
-
资助金额:$6.58万
-
财政年份:2019
-
负责人:JOHN Hackett BUSHWELLER
-
依托单位:
AF9(MLLT3) Function in Leukemia and Normal Hematopoiesis
-
批准号:10198868
-
项目类别:
-
资助金额:$60.18万
-
财政年份:2019
-
负责人:JOHN Hackett BUSHWELLER
-
依托单位:
AF9(MLLT3) Function in Leukemia and Normal Hematopoiesis
-
批准号:10738333
-
项目类别:
-
资助金额:$6.58万
-
财政年份:2019
-
负责人:JOHN Hackett BUSHWELLER
-
依托单位:
Targeted Small Molecule Inhibitors for Inv(16) Leukemia
-
批准号:10307548
-
项目类别:
-
资助金额:$66.72万
-
财政年份:2018
-
负责人:JOHN Hackett BUSHWELLER
-
依托单位:
Targeted Small Molecule Inhibitors for Inv(16) Leukemia
-
批准号:10520054
-
项目类别:
-
资助金额:$66.69万
-
财政年份:2018
-
负责人:JOHN Hackett BUSHWELLER
-
依托单位:
Targeted Small Molecule Inhibitors for Inv(16) Leukemia
-
批准号:10056213
-
项目类别:
-
资助金额:$67.89万
-
财政年份:2018
-
负责人:JOHN Hackett BUSHWELLER
-
依托单位:
Structure/Function of AF9 and MLL-AF9
-
批准号:8974717
-
项目类别:
-
资助金额:$0.83万
-
财政年份:2014
-
负责人:JOHN Hackett BUSHWELLER
-
依托单位:
Structure/Function of AF9 and MLL-AF9
-
批准号:8311653
-
项目类别:
-
资助金额:$46.68万
-
财政年份:2011
-
负责人:JOHN Hackett BUSHWELLER
-
依托单位:
Structure/Function of AF9 and MLL-AF9
-
批准号:8504799
-
项目类别:
-
资助金额:$43.88万
-
财政年份:2011
-
负责人:JOHN Hackett BUSHWELLER
-
依托单位:
Structure/Function of AF9 and MLL-AF9
-
批准号:8193766
-
项目类别:
-
资助金额:$49.71万
-
财政年份:2011
-
负责人:JOHN Hackett BUSHWELLER
-
依托单位:
Structure/Function of AF9 and MLL-AF9
-
批准号:8677790
-
项目类别:
-
资助金额:$45.28万
-
财政年份:2011
-
负责人:JOHN Hackett BUSHWELLER
-
依托单位:
Development of Inhibitors of the Leukemia Fusion Protein CBFbeta-SMMHC
-
批准号:8071203
-
项目类别:
-
资助金额:$64.24万
-
财政年份:2010
-
负责人:JOHN Hackett BUSHWELLER
-
依托单位:
Development of Inhibitors of the Leukemia Fusion Protein CBFbeta-SMMHC
-
批准号:8457974
-
项目类别:
-
资助金额:$59.31万
-
财政年份:2010
-
负责人:JOHN Hackett BUSHWELLER
-
依托单位:
Development of Inhibitors of the Leukemia Fusion Protein CBFbeta-SMMHC
-
批准号:7892198
-
项目类别:
-
资助金额:$68.69万
-
财政年份:2010
-
负责人:JOHN Hackett BUSHWELLER
-
依托单位:
Solution NMR Structure and Function of the Integral Membrane Protein DsbB
-
批准号:7811029
-
项目类别:
-
资助金额:$17.6万
-
财政年份:2010
-
负责人:JOHN Hackett BUSHWELLER
-
依托单位:
Development of Inhibitors of the Leukemia Fusion Protein CBFbeta-SMMHC
-
批准号:8242873
-
项目类别:
-
资助金额:$63.09万
-
财政年份:2010
-
负责人:JOHN Hackett BUSHWELLER
-
依托单位:
海外基金